» Articles » PMID: 33535429

The Contribution of the Urokinase Plasminogen Activator and the Urokinase Receptor to Pleural and Parenchymal Lung Injury and Repair: A Narrative Review

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Feb 4
PMID 33535429
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Pleural and parenchymal lung injury have long been characterized by acute inflammation and pathologic tissue reorganization, when severe. Although transitional matrix deposition is a normal part of the injury response, unresolved fibrin deposition can lead to pleural loculation and scarification of affected areas. Within this review, we present a brief discussion of the fibrinolytic pathway, its components, and their contribution to injury progression. We review how local derangements of fibrinolysis, resulting from increased coagulation and reduced plasminogen activator activity, promote extravascular fibrin deposition. Further, we describe how pleural mesothelial cells contribute to lung scarring via the acquisition of a profibrotic phenotype. We also discuss soluble uPAR, a recently identified biomarker of pleural injury, and its diagnostic value in the grading of pleural effusions. Finally, we provide an in-depth discussion on the clinical importance of single-chain urokinase plasminogen activator (uPA) for the treatment of loculated pleural collections.

Citing Articles

Elevated international normalized ratio contributes to poor prognosis in patients with traumatic lung injury.

Lin Q, Peng E, Deng X, Song X, Zhong L, He L Front Med (Lausanne). 2024; 11:1426999.

PMID: 39156692 PMC: 11327037. DOI: 10.3389/fmed.2024.1426999.


Urokinase-Type Plasminogen Activator Receptor (uPAR) in Inflammation and Disease: A Unique Inflammatory Pathway Activator.

Hamada M, Varkoly K, Riyadh O, Beladi R, Munuswamy-Ramanujam G, Rawls A Biomedicines. 2024; 12(6).

PMID: 38927374 PMC: 11201033. DOI: 10.3390/biomedicines12061167.


The mTORC2/SGK1/NDRG1 Signaling Axis Is Critical for the Mesomesenchymal Transition of Pleural Mesothelial Cells and the Progression of Pleural Fibrosis.

Keshava S, Owens S, Qin W, Jeffers A, Kyei P, Komatsu S Am J Respir Cell Mol Biol. 2023; 70(1):50-62.

PMID: 37607215 PMC: 10768834. DOI: 10.1165/rcmb.2023-0131OC.


The Association of Genotype and Soluble suPAR Serum Level with COVID-19-Related Lung Damage Severity.

Nekrasova L, Shmakova A, Samokhodskaya L, Kirillova K, Stoyanova S, Mershina E Int J Mol Sci. 2022; 23(24).

PMID: 36555850 PMC: 9785175. DOI: 10.3390/ijms232416210.


Is the Urokinase Plasminogen Activator/Plasminogen Activator Inhibitor-1 Ratio a Marker of Sonographic Septations in Pleural Infection?.

Yasuma T, DAlessandro-Gabazza C, Kobayashi T, Gabazza E, Fujimoto H Am J Respir Crit Care Med. 2022; 207(7):949.

PMID: 36413774 PMC: 10111981. DOI: 10.1164/rccm.202210-1916LE.


References
1.
Eitzman D, McCoy R, Zheng X, Fay W, Shen T, Ginsburg D . Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest. 1996; 97(1):232-7. PMC: 507084. DOI: 10.1172/JCI118396. View

2.
Arnold D, Hamilton F, Elvers K, Frankland S, Zahan-Evans N, Patole S . Pleural Fluid suPAR Levels Predict the Need for Invasive Management in Parapneumonic Effusions. Am J Respir Crit Care Med. 2020; 201(12):1545-1553. PMC: 7301729. DOI: 10.1164/rccm.201911-2169OC. View

3.
Bouros D, Schiza S, Tzanakis N, Chalkiadakis G, Drositis J, Siafakas N . Intrapleural urokinase versus normal saline in the treatment of complicated parapneumonic effusions and empyema. A randomized, double-blind study. Am J Respir Crit Care Med. 1999; 159(1):37-42. DOI: 10.1164/ajrccm.159.1.9803094. View

4.
Idell S, Koenig K, Fair D, Martin T, McLarty J, Maunder R . Serial abnormalities of fibrin turnover in evolving adult respiratory distress syndrome. Am J Physiol. 1991; 261(4 Pt 1):L240-8. DOI: 10.1152/ajplung.1991.261.4.L240. View

5.
Lechowicz K, Drozdzal S, Machaj F, Rosik J, Szostak B, Zegan-Baranska M . COVID-19: The Potential Treatment of Pulmonary Fibrosis Associated with SARS-CoV-2 Infection. J Clin Med. 2020; 9(6). PMC: 7356800. DOI: 10.3390/jcm9061917. View